Konstanze Döhner studied Medicine at the University Medical School in Heidelberg, Germany and received her M.D. degree in 1992. From the beginning she worked in the field of hematology with a special focus on myeloid malignancies, in particular acute myeloid leukemia (AML). From 1995 to 1997 she spent a postdoctoral fellowship at the German Cancer Research Center (Professor Dr. Peter Lichter) in Heidelberg, Germany, and the Hospital for Sick Children, Department of Genetics (Dr. S.W. Scherer) Toronto, Canada. Her main scientific interest was the molecular characterization of AML and the translation of her findings into clinical studies. Very early she became a member of the German-Austrian AML Study Group (AMLSG) and here she established one of the leading reference laboratories for molecular diagnostics in AML. The identification of molecular markers within a very short time window (48hrs) was a major basis for the development of risk-adapted treatment regimens as performed within the AMLSG. In 2000 Konstanze Döhner moved to the Department of Hematology/Oncology at the University Hospital Ulm (Germany) and worked as a consultant. She became head of the laboratory for Cytogenetic and Molecular Diagnostics in myeloid leukemias. In 2003 Konstanze Döhner received her board certification as Hematologist and Oncologist and in 2005 she finished her “Habilitation” and became Professor. Konstanze Döhner is involved in a large number of clinical AML studies. She is member of the European LeukemiaNet MRD working party. In 2018 she was elected as a Board Member of the European Hematology Association (EHA); in 2019 she became a member of the EHA Education committee. In addition, Konstanze Döhner was elected as a member of the Scientific Committee for Myeloid Neoplasia of the American Society of Hematology (ASH). Beside AML she also has clinical and scientific interest in myeloproliferative neoplasms. Here she is one of the founders of the German Study Group on Myeloproliferative Neoplasms (GSG-MPN). Konstanze Döhner is involved in a number of national and international scientific cooperations which is also reflected by numerous highly ranked publications.
-State-of-the-Art lecture K. Döhner (Germany) -Next Generation Sequencing in AML: to whom, why and when? R. Antolić Margarita (Croatia) -Flt3 positive AML patients: Experience of single center N. Suvajdžić Vuković (Serbia) -How we can treat unfit AML patients? A. Vidović (Serbia) -Title to be announced A. Cili (Albania) -Panel discussion /All speakers